# Semax

> A seven-amino-acid ACTH fragment analogue that FDA reports is registered in Russia. Its human studies are small, mostly Russian, and not placebo-randomised.

Source page: https://peptioresearch.com/peptides/semax/
Publisher: Peptio Research. Educational summary of published research, not medical advice.
Last checked against its sources: 2026-10-11

## At a glance

- Research status: In clinical trials
- Also known as: Semaks, ACTH(4-7)-Pro-Gly-Pro, ACTH(4-7)PGP, MEHFPGP, Met-Glu-His-Phe-Pro-Gly-Pro
- Identifiers: CAS 80714-61-0; PubChem CID 9811102
- Molecular weight: 813.9
- Sequence: MEHFPGP

## What the research shows

Each claim is labelled with the strongest kind of study that supports it, which way the evidence points, and how confident that reading is.

### In healthy volunteers, the only placebo-controlled human studies found measured resting-state brain networks by fMRI within 20 minutes of a single administration, not memory, attention or any other cognitive test.

- Evidence: Human case report. Insufficient evidence. Very low confidence.
- Sources: [1][2][3]

Lebedeva and colleagues (2018) scanned 24 healthy volunteers, 10 of them on placebo, before and 5 and 20 minutes after administration, and report "a greater volume of the default mode network rostral (medial frontal cortex) subcomponent" in the semax group. Panikratova and colleagues (2020) scanned 52 healthy participants given semax, selank or placebo and report differences in functional connectivity of the right amygdala. Neither abstract reports a cognitive or behavioural outcome. The claim that semax improves memory and attention in healthy people traces, in the sources found, to a 1997 overview by its developers that reports it "significantly improves memory and attention in healthy men under extreme conditions of activities" without naming a test, design or sample size.

Caveats:
- A change in a resting-state network is a surrogate, not a change in how someone thinks or functions.
- Neither abstract says allocation was random or that the studies were blinded.
- FDA's briefing notes the semax subjects in the two studies "appear to be very similar" and that it is unclear whether the same people took part in both, so the two samples should not be added together.
- The 1997 overview is a narrative summary of the developers' own work, not a primary study. Abstracts only.

### In 110 patients after ischaemic stroke, a comparison whose abstract does not describe randomisation reported higher plasma BDNF, a laboratory marker, and better Barthel index scores of daily living with semax added to rehabilitation, without effect sizes in the abstract.

- Evidence: Human case report. Supportive. Very low confidence.
- Sources: [4]

Gusev and colleagues (2018) divided 110 stroke patients into early and late rehabilitation groups, each with semax and no-semax subgroups, and measured plasma BDNF, the British Medical Research Council motor scale and the Barthel index. They report that semax "increased BDNF plasma levels" regardless of rehabilitation timing, and that semax and high BDNF "accelerated the improvement and ameliorated the final outcome of Barthel score index".

Caveats:
- Randomisation and blinding are not described. Subgroup sizes and effect sizes are not in the abstract.
- Russian-language paper; only the English abstract was read.

### In earlier Russian studies of ischaemic stroke and cerebrovascular insufficiency (30 patients against 80 controls, and 187 patients with no stated comparator), authors reported faster recovery on unnamed neurological scales; a further retrospective analysis reported shifts in cytokines and C-reactive protein, laboratory markers.

- Evidence: Human case report. Supportive. Very low confidence.
- Sources: [5][6][7]

Gusev and colleagues (1997) compared 30 patients in the acute period of hemispheric ischaemic stroke with 80 patients of similar severity on conventional therapy, using clinical rating scales not named in the abstract, EEG mapping and evoked potentials, and report semax "had some influence on the rate of restoration of the damaged neurological functions". A 2005 study of 187 patients with cerebrovascular insufficiency reports "significant clinical improvement" on neurological scales and a reduced risk of stroke and transient ischaemic attacks, with no comparison group stated. A 1999 retrospective analysis reports a shift towards interleukin-10 over interleukin-8 and C-reactive protein.

Caveats:
- None of the abstracts describes random allocation or blinding, and none gives figures.
- With no comparator stated in the 2005 abstract, its "reduced risk" has no stated reference group.
- These are among the Russian-language papers FDA did not consider, for language. Only English abstracts were read.

### In 27 people with motor neuron disease, an open-label study found no effect on needle EMG, the Norris ALS scale or the ALS Functional Rating Scale, and reported better scores only on ALSAQ-40, a patient-reported quality of life questionnaire.

- Evidence: Human case report. Mixed. Very low confidence.
- Sources: [8]

Serdiuk and colleagues (2007) report that semax "does not influence either the course of CPD or the dynamics of clinical estimates" but "significantly improves the total estimate of life quality".

Caveats:
- PubMed indexes it as a randomised controlled trial, but the abstract describes an "open-label clinical trial" in "sequential groups of patients", so it is graded below an RCT here.
- The only positive result is on an unblinded patient-reported scale. Abstract only.

### In people with refractory peptic ulcer, ulcer healing at day 14 was reported in 89.5% of those given intranasal semax with standard ulcer drugs against 30.8% on standard drugs alone, in a study whose abstract states no sample size or allocation method.

- Evidence: Human case report. Supportive. Very low confidence.
- Sources: [9]

Ivanikov and colleagues (2002) added semax to omeprazole, De-Nol and Solcoseryl and compared ulcer healing with those drugs alone. The authors write that further clinical studies of semax with usual antiulcer drugs "are needed".

Caveats:
- The abstract does not give the number of patients or say allocation was random or blinded. Abstract only.

### In Russian studies of eye disease (optic nerve disease, glaucomatous optic neuropathy, diabetic retinopathy in 114 patients, vascular optic neuropathy in 60, retinal detachment surgery in 42), authors reported better visual acuity, visual field or electrophysiological measures, mostly with semax added to other treatment.

- Evidence: Human case report. Supportive. Very low confidence.
- Sources: [10][11][12][13][14]

The studies measured visual acuity, perimetry, microperimetry, electrical sensitivity and electrophysiology. In the vascular optic neuropathy study semax was one part of a combined neurostimulation package, and in the retinal detachment study both groups received semax, so neither tests semax against no semax.

Caveats:
- No abstract describes random allocation or blinding, and most give no figures.
- Because semax was usually combined with other treatment, its own contribution cannot be separated. Abstracts only.

### In 73 patients with posthypoxic encephalopathy, an uncontrolled series reported semax "effective in patients with mnestic disorders", meaning memory disorders, without naming a test.

- Evidence: Human case report. Supportive. Very low confidence.
- Sources: [15]

Alekseeva and colleagues (1999) treated 73 patients in the remote period after hypoxic brain injury, 14 of whom were in a persistent vegetative state. No control group is mentioned.

Caveats:
- No control group, no named memory test and no figures in the abstract. Abstract only.

### In rats with focal ischaemia of the prefrontal cortex, intranasal semax for 6 days reduced cortical infarct volume and improved retention of a conditioned passive avoidance response; in rats with incomplete global ischaemia it reduced signs of tissue damage.

- Evidence: Animal research. Supportive. Low confidence.
- Sources: [16][17][18]

Romanova and colleagues (2006) report semax "decreased the volume of cortical infarction" in rats after photoinduced ischaemia. Stavchansky and colleagues (2011), in a pilot study in male Wistar rats, report that "only Semax abated the manifestation of ischemic damage to the nervous tissue". In male Wistar rats with permanent middle cerebral artery occlusion, semax changed the expression of immune and vascular genes, a measure of transcription rather than outcome.

Caveats:
- Group sizes are not given in the abstracts. Most of this work comes from Russian research groups.
- Rat outcomes do not establish an effect in people with stroke.

### In rat hippocampus, semax raised BDNF protein up to 1.4-fold and BDNF mRNA 3-fold, laboratory markers of a neurotrophic factor, and increased conditioned avoidance reactions.

- Evidence: Animal research. Supportive. Low confidence.
- Sources: [19][20]

Dolotov and colleagues (2006) report "a maximal 1.4-fold increase of BDNF protein levels" and "a 3-fold and a 2-fold increase of exon III BDNF and trkB mRNA levels" in rat hippocampus. Agapova and colleagues (2007) report raised hippocampal BDNF and NGF mRNA in Wistar rats an hour after an intranasal dose, while "Ngf gene expression decreased in rat frontal cortex."

Caveats:
- These fold changes are in rat brain tissue, not human blood. Group sizes are not in the abstracts.

### In male C57BL mice, semax alone did not change striatal dopamine but, given with amphetamine, dramatically enhanced amphetamine's effect on extracellular dopamine and on locomotor activity.

- Evidence: Animal research. Supportive. Low confidence.
- Sources: [21]

Eremin and colleagues (2005) report that semax "failed to alter the tissue and extracellular concentrations of dopamine" on its own, raised the serotonin metabolite 5-HIAA by 25% in striatal tissue, and with amphetamine "dramatically enhanced the effects of the latter on the extracellular level of dopamine".

Caveats:
- A mouse study. No study of whether semax itself has addictive properties was identified by FDA.

### In laboratory tests with rat blood and serum, semax was broken down mainly by aminopeptidases and angiotensin-converting enzyme, and was more stable than ACTH(4-10); no half-life in people has been published in the sources found.

- Evidence: In-vitro. Supportive. Low confidence.
- Sources: [22][23][24]

Potaman and colleagues (1991) report that aminopeptidase "cleaved first and second N-terminal residues Met and Glu" and that semax "turned out to be more stable than ACTH(4-10)" against other enzymes. A 1993 study in rat serum names "aminopeptidases and angiotensin-converting enzyme" as responsible for most of the breakdown. FDA's briefing states it could not find pharmacokinetic studies in humans by any route.

Caveats:
- Rat material in a test tube. Abstracts only for the two studies.

## Reported and theoretical risks

### EEG paroxysmal activity in some patients

- Evidence: Human case report. Severity: unknown.
- Sources: [15]

In an uncontrolled series of 73 patients with posthypoxic encephalopathy, the authors report that "In some cases EEG showed episodes of paroxysmal activity after semax injection". The abstract gives no frequency or clinical consequence.

### Tolerability statements come from studies not designed to detect harm

- Evidence: Human case report. Severity: unknown.
- Sources: [6][24]

A 2005 study of 187 patients with cerebrovascular insufficiency describes a "minor percent of side-effects" without figures. FDA's briefing states that "Most of the references did not discuss safety" and that it found "insufficient clinical information to characterize the safety profile". Absence of reported harm in small uncontrolled studies is not evidence of safety.

### One adverse event report of eye pain with hospitalisation

- Evidence: Mechanistic reasoning. Severity: unknown.
- Sources: [24]

FDA's briefing reports that a search of its adverse event database "retrieved one FAERS report", in which a consumer reported "ocular pain and eye burning" after using semax nasal drops bought online, with hospitalisation and eye pain that had not resolved a year later. A single spontaneous report does not establish cause. FDA also "did not identify literature case reports of AEs in humans".

### Possible bleeding risk, raised by FDA from animal data

- Evidence: Mechanistic reasoning. Severity: theoretical.
- Sources: [24]

FDA's briefing, describing rat studies and a human meeting abstract it did not have full results for, states that possible anti-thrombotic properties of semax raise "concern about the risk of bleeding, particularly in certain populations at risk for bleeding or if combined with other medications that increase bleeding risk". No bleeding event in a person is documented in the sources found.

### Unknown abuse potential

- Evidence: Animal research. Severity: theoretical.
- Sources: [21][24]

In mice, semax enhanced amphetamine-induced dopamine release in the striatum. FDA calls this "concerning because increased dopaminergic tone in the striatum is a response typically induced by drugs of abuse such as cocaine" and states that it "did not identify nonclinical studies to demonstrate whether semax has reinforcing and addictive properties".

### Immunogenicity and impurities in compounded products

- Evidence: Mechanistic reasoning. Severity: unknown.
- Sources: [25]

FDA states that compounded drugs containing semax "may pose risk for immunogenicity for certain routes of administration" "due to the potential for aggregation and peptide-related impurities", and that "the agency lacks sufficient information to know whether the drug would cause harm if administered to humans."

### No human pharmacokinetic or standard toxicology data

- Evidence: Mechanistic reasoning. Severity: unknown.
- Sources: [24]

FDA's briefing states: "We were not able to find pharmacokinetic studies in humans following exposure to semax (free base) or semax acetate via any ROA", and identified no acute, repeat-dose, reproductive or two-year carcinogenicity studies. It also states: "There are no safety data for semax (free base) and semax acetate administered by the proposed SC ROA."

## Regulatory status

- US, FDA: not approved (as of 2026-07-24). FDA's briefing document for the July 2026 Pharmacy Compounding Advisory Committee concludes that "a balancing of the criteria weighs against semax (free base) or semax acetate being placed on that list", the 503A bulks list, and proposes "not adding semax (free base) or semax acetate to the 503A Bulks List". It states that semax is not a component of an FDA-approved drug and has no USP or NF monograph. For effectiveness, FDA states that the two references it could assess "demonstrated lack of effectiveness" for the three uses reviewed, and it set aside Russian-language clinical papers on cerebral ischaemia because "the full references were not available in English". It says its proposal rests "in particular" on semax not being well characterised physicochemically, then on missing safety information, immunogenicity concerns and the existence of approved treatments. [24]
- RU, State Register of Medicines (as reported by FDA): unclear (as of 2026-07-24). Second hand: FDA's July 2026 briefing states that "Semax is a registered drug in Russia", available as nasal drops, citing the Russian State Register of Medicinal Products. This site could not retrieve the register entry or any Russian regulator document, so the registered indications, holder and date are not known here. [24]
- US, FDA: unclear (as of 2026-08-06). FDA's Pharmacy Compounding Advisory Committee page lists "Semax (free base)" and "Semax acetate" for 24 July 2026, for the uses "Cerebral ischemia, migraine, and trigeminal neuralgia". The page, reopened on 6 November 2026, records no vote or outcome. [26]
- US, FDA advisory committee: unclear (as of 2026-11-06). Second hand: a law firm and a trade journal both report that the committee voted to recommend adding Semax to the 503A bulks list at its 23-24 July 2026 meeting, against FDA's own proposal. Neither gives the count, or says whether the vote covers the free base, the acetate or both. FDA's meeting page, reopened on 6 November 2026, posts no vote record, though HHS's October 2026 policy states that the committee voted in favour of both forms. The vote is advice: it does not place semax on the 503A bulks list, which needs FDA to accept it and complete rulemaking. [27]
- US, HHS: not approved (as of 2026-11-02). HHS's enforcement discretion policy, noticed in the Federal Register on 30 October 2026, says HHS does not intend to act against a state-licensed pharmacy, federal facility or licensed physician compounding semax free base, for intranasal use, when ten listed conditions are met, among them a patient-specific prescription and a single active ingredient. It does not approve the substance or add it to the 503A bulks list, and it runs until a final rule addresses the substance. The Federal Register notice calls it a draft, takes comments for two weeks after publication and says it is not binding. HHS records that CDER, FDA's drug centre, recommended against listing; HHS cites an intranasal record of "several hundred subjects with no reported adverse outcome". FDA's briefing, from which that record comes, says adverse events were reported as absent in one reference and not discussed in the others, and it records one FAERS report of eye pain with hospitalisation after nasal drops. The policy makes no finding that the substance works. [28]
- US, FDA: unclear (as of 2026-04-22). FDA lists "Semax (heptapeptide)" in the table "Bulk drug substances nominated but withdrawn", stating: "Compounded drugs containing semax (heptapeptide) may pose risk for immunogenicity for certain routes of administration due to the potential for aggregation and peptide-related impurities. FDA has no, or limited, safety-related information for proposed routes of administration. Therefore, the agency lacks sufficient information to know whether the drug would cause harm if administered to humans." [25]
- US, FDA: unclear (as of 2026-05-14). FDA's 503A bulk drug substance categories list updated on 14 May 2026 has no entry for semax in any category. [29]

## Context

Semax has been studied in people, but almost all of the human studies come from Russian groups, and none of the abstracts read states random allocation and blinding against placebo with a clinical outcome. In healthy people, the placebo-controlled work measured brain activity by fMRI, not memory or attention ([source](https://pubmed.ncbi.nlm.nih.gov/30225715/)). Searches found no registered trial on ClinicalTrials.gov and no systematic review. FDA reports that semax is registered as a drug in Russia; this site could not retrieve a Russian register document. In its July 2026 briefing FDA weighed against adding semax to the 503A compounding list, mainly because semax is not well characterised as a substance, and also for lack of safety and effectiveness information. It found the two references it could assess showed "lack of effectiveness", and it did not consider Russian-language stroke papers whose full texts were not available in English ([source](https://www.fda.gov/media/193348/download)).

## What it is

Semax is a chain of seven amino acids, Met-Glu-His-Phe-Pro-Gly-Pro, or MEHFPGP, as FDA's briefing gives it ([source](https://www.fda.gov/media/193348/download)). Published studies describe it as an analogue of the 4-10 fragment of adrenocorticotropic hormone (ACTH), the pituitary hormone that drives cortisol release ([source](https://pubmed.ncbi.nlm.nih.gov/16996037/)). Its formula is C37H51N9O10S and its molecular weight 813.9 ([source](https://pubchem.ncbi.nlm.nih.gov/compound/9811102)).

FDA describes it as a synthetic analogue of the ACTH 4-10 fragment and, citing a review, as lacking the hormonal effects of full ACTH ([source](https://www.fda.gov/media/193348/download)). FDA treats semax free base and semax acetate as different substances, and notes that the clinical papers do not say which form was used. Semax is a common name, not an approved nonproprietary name. N-acetyl and other modified forms are different substances and are not covered here. Selank is a separate peptide.

## Cognition in healthy people

> **Key point.**
> No abstract found measured memory, attention or any cognitive test against placebo in healthy people. The two placebo-controlled studies measured resting-state brain networks by fMRI within 20 minutes of one administration ([source](https://pubmed.ncbi.nlm.nih.gov/30225715/), [source](https://pubmed.ncbi.nlm.nih.gov/32342318/)).

In 24 healthy volunteers, 10 of them on placebo, Lebedeva and colleagues report a larger medial frontal part of the default mode network, a set of brain regions active at rest ([source](https://pubmed.ncbi.nlm.nih.gov/30225715/)). A 2020 study of 52 healthy participants found changes in amygdala connectivity ([source](https://pubmed.ncbi.nlm.nih.gov/32342318/)). FDA notes the two studies may share participants ([source](https://www.fda.gov/media/193348/download)).

The claim that semax improves memory and attention in healthy people traces, in the sources found, to a 1997 overview by its developers, which names no test or sample size ([source](https://pubmed.ncbi.nlm.nih.gov/9173745/)).

## Stroke and other conditions

In 110 patients after ischaemic stroke, a comparison whose abstract does not describe randomisation reported higher plasma BDNF, a neurotrophic factor measured in blood, and better Barthel index scores of daily living with semax added to rehabilitation ([source](https://pubmed.ncbi.nlm.nih.gov/29798983/)). Earlier studies, of 30 stroke patients against 80 controls and of 187 patients with no stated comparator, report faster recovery on neurological scales the abstracts do not name ([source](https://pubmed.ncbi.nlm.nih.gov/11517472/), [source](https://pubmed.ncbi.nlm.nih.gov/15792140/)).

> **Evidence.**
> In 27 people with motor neuron disease, semax did not change needle EMG or two ALS rating scales; only a patient-reported quality of life score improved. PubMed tags the study as randomised, but its abstract calls it "open-label" in "sequential groups of patients" ([source](https://pubmed.ncbi.nlm.nih.gov/18379501/)).

Smaller Russian studies report benefits in eye disease, usually with semax added to other treatment ([source](https://pubmed.ncbi.nlm.nih.gov/24437205/), [source](https://pubmed.ncbi.nlm.nih.gov/36083821/)), and in refractory peptic ulcer, where healing at day 14 was 89.5% against 30.8% in an abstract that gives no sample size ([source](https://pubmed.ncbi.nlm.nih.gov/12459874/)).

> **Limitation.**
> Only English abstracts of these papers were read. None describes random allocation or blinding, most add semax to other therapy, and most come from Russian research groups.

## In animals

In rats with focal ischaemia of the prefrontal cortex, semax reduced infarct volume and improved a conditioned avoidance task ([source](https://pubmed.ncbi.nlm.nih.gov/17603664/)). In rat hippocampus it raised BDNF protein up to 1.4-fold ([source](https://pubmed.ncbi.nlm.nih.gov/16996037/)). In male mice, semax alone left striatal dopamine unchanged but strongly enhanced the dopamine and locomotor response to amphetamine ([source](https://pubmed.ncbi.nlm.nih.gov/16362768/)).

## Regulatory position

FDA's advisory committee considered semax free base and semax acetate on 24 July 2026 for cerebral ischaemia, migraine and trigeminal neuralgia ([source](https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026)). FDA's briefing concluded that "a balancing of the criteria weighs against" placing it on the 503A list ([source](https://www.fda.gov/media/193348/download)). Its proposal rests "in particular" on semax not being well characterised physicochemically, then on missing safety information, immunogenicity concerns and approved alternatives. On effectiveness, it found that the only two references it could assess, with insufficient detail on design and conduct, "demonstrated lack of effectiveness" for cerebral ischaemia, migraine and trigeminal neuralgia; it states the Russian papers "were not considered as part of this evaluation" because full texts were not available in English. Those papers exist, and on their own abstracts they are not controlled trials either. Press and legal reports, which are second hand, say the committee nonetheless voted to recommend semax for the list, by what the trade journal calls a similarly tight margin, without a count; FDA had posted no vote record by 6 November 2026, and a recommendation does not put it on the list ([source](https://www.ajmc.com/view/fda-panel-backs-6-peptides-for-compounding), [source](https://www.hklaw.com/en/insights/publications/2026/10/peptides-at-a-crossroads-what-wellness-providers-need-to-know)). In October 2026 HHS, FDA's parent department, said it does not intend to act against compounders of semax free base, for intranasal use, who meet ten listed conditions, while recording that CDER, FDA's drug centre, recommended against listing ([source](https://www.hhs.gov/sites/default/files/hhs-503a-peptide-enforcement-discretion-policy-appendix-b.pdf)). The notice calls that policy a non-binding draft ([source](https://www.govinfo.gov/content/pkg/FR-2026-10-30/pdf/2026-22192.pdf)); it is not an approval and it does not add semax to the list.

FDA lists semax among bulk substances nominated for compounding but withdrawn ([source](https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks)). It has no entry in any category of the 503A list updated 14 May 2026 ([source](https://www.fda.gov/media/94155/download)). Russian registration is reported here as FDA states it; the indications are not known from a Russian source.

> **Caution.**
> FDA states that compounded semax may carry a risk of immune reactions for certain routes of administration, that no pharmacokinetic study in humans was found, and that animal data raise questions about bleeding and abuse potential that have not been studied ([source](https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks), [source](https://www.fda.gov/media/193348/download)).

## Sources

1. Lebedeva IS et al. Effects of Semax on the Default Mode Network of the Brain. Bulletin of Experimental Biology and Medicine. 2018. https://doi.org/10.1007/s10517-018-4234-3
2. Panikratova YR et al. Functional Connectomic Approach to Studying Selank and Semax Effects. Doklady Biological Sciences. 2020. https://doi.org/10.1134/S001249662001007X
3. Asmarin IP et al. [A nootropic adrenocorticotropin analog 4-10-semax (15 years experience in its design and study)]. Zhurnal vysshei nervnoi deiatelnosti imeni I P Pavlova. 1997. https://pubmed.ncbi.nlm.nih.gov/9173745/
4. Gusev EI et al. [The efficacy of semax in the tretament of patients at different stages of ischemic stroke]. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. 2018. https://doi.org/10.17116/jnevro20181183261-68
5. Gusev EI et al. [Effectiveness of semax in acute period of hemispheric ischemic stroke (a clinical and electrophysiological study)]. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. 1997. https://pubmed.ncbi.nlm.nih.gov/11517472/
6. Gusev EI, Skvortsova VI, Chukanova EI. [Semax in prevention of disease progress and development of exacerbations in patients with cerebrovascular insufficiency]. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. 2005. https://pubmed.ncbi.nlm.nih.gov/15792140/
7. Miasoedova NF et al. [Investigation of mechanisms of neuro-protective effect of semax in acute period of ischemic stroke]. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. 1999. https://pubmed.ncbi.nlm.nih.gov/10358912/
8. Serdiuk AV et al. [The study of chronic partial denervation and quality of life in patients with motor neuron disease treated with semax]. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. 2007. https://pubmed.ncbi.nlm.nih.gov/18379501/
9. Ivanikov IO et al. Therapy of peptic ulcer with semax peptide. Bulletin of Experimental Biology and Medicine. 2002. https://doi.org/10.1023/a:1020621124776
10. Polunin GS et al. [Evaluation of therapeutic effect of new Russian drug semax in optic nerve disease]. Vestnik oftalmologii. 2000. https://pubmed.ncbi.nlm.nih.gov/10741256/
11. Kurysheva NI et al. [Semax in the treatment of glaucomatous optic neuropathy in patients with normalized ophthalmic tone]. Vestnik oftalmologii. 2001. https://pubmed.ncbi.nlm.nih.gov/11569188/
12. Nazarova GA et al. [The results of the application of the pre-formed physical factors and neuroprotective therapy for the rehabilitative treatment of the patients with diabetic retinopathy]. Voprosy kurortologii, fizioterapii, i lechebnoi fizicheskoi kultury. 2013. https://pubmed.ncbi.nlm.nih.gov/24437205/
13. Dragon AK et al. [Results of the application of complex physiotherapeutic neurostimulation in optical neuropathies of various genesis]. Voprosy kurortologii, fizioterapii, i lechebnoi fizicheskoi kultury. 2022. https://doi.org/10.17116/kurort20229904272
14. Sheludchenko VM et al. [Effect of a combined physiotherapeutic approach on changes in functional parameters after endovitreal surgery of rhegmatogenous retinal detachment with a favorable anatomical outcome]. Vestnik oftalmologii. 2026. https://doi.org/10.17116/oftalma202614203129
15. Alekseeva GV, Bottaev NA, Goroshkova VV. [Use of semax at a follow-up of patients with posthypoxic encephalopathy]. Anesteziologiia i reanimatologiia. 1999. https://pubmed.ncbi.nlm.nih.gov/10199046/
16. Romanova GA et al. Neuroprotective and antiamnesic effects of Semax during experimental ischemic infarction of the cerebral cortex. Bulletin of Experimental Biology and Medicine. 2006. https://doi.org/10.1007/s10517-006-0445-0
17. Stavchansky VV et al. The effect of Semax and its C-end peptide PGP on the morphology and proliferative activity of rat brain cells during experimental ischemia: a pilot study. Journal of Molecular Neuroscience. 2011. https://doi.org/10.1007/s12031-010-9421-2
18. Medvedeva EV et al. The peptide semax affects the expression of genes related to the immune and vascular systems in rat brain focal ischemia: genome-wide transcriptional analysis. BMC Genomics. 2014. https://doi.org/10.1186/1471-2164-15-228
19. Dolotov OV et al. Semax, an analog of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus. Brain Research. 2006. https://doi.org/10.1016/j.brainres.2006.07.108
20. Agapova TY et al. Neurotrophin gene expression in rat brain under the action of Semax, an analogue of ACTH 4-10. Neuroscience Letters. 2007. https://doi.org/10.1016/j.neulet.2007.02.042
21. Eremin KO et al. Semax, an ACTH(4-10) analogue with nootropic properties, activates dopaminergic and serotoninergic brain systems in rodents. Neurochemical Research. 2005. https://doi.org/10.1007/s11064-005-8826-8
22. Potaman VN et al. N-terminal degradation of ACTH(4-10) and its synthetic analog semax by the rat blood enzymes. Biochemical and Biophysical Research Communications. 1991. https://doi.org/10.1016/s0006-291x(05)80247-5
23. Potaman VN et al. Degradation of ACTH/MSH(4-10) and its synthetic analog semax by rat serum enzymes: an inhibitor study. Peptides. 1993. https://doi.org/10.1016/0196-9781(93)90137-6
24. FDA Briefing Document: Semax-Related Bulk Drug Substances (Semax (free base) and Semax acetate), Pharmacy Compounding Advisory Committee, July 23-24, 2026. U.S. Food and Drug Administration. 2026. https://www.fda.gov/media/193348/download
25. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. U.S. Food and Drug Administration. 2026. https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
26. July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee. U.S. Food and Drug Administration. 2026. https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026
27. Crossan SS, Watkins S. Peptides at a Crossroads: What Wellness Providers Need to Know About HHS and FDA Actions. Holland & Knight Alert. 2026. https://www.hklaw.com/en/insights/publications/2026/10/peptides-at-a-crossroads-what-wellness-providers-need-to-know
28. HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, with Appendices A and B. U.S. Department of Health and Human Services. 2026. https://www.hhs.gov/sites/default/files/hhs-503a-peptide-enforcement-discretion-policy-appendix-b.pdf
29. Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act, updated May 14, 2026. U.S. Food and Drug Administration. 2026. https://www.fda.gov/media/94155/download
